The risk classification for NPM1 and FLT3-ITD genotypes in the 2017 ELN recommendations is presented in Table 2 [4] and was validated in a large retrospective analysis in patients with newly diagnosed AML and intermediate-risk cytogenetic abnormalities or normal karyotype [8]. This evidence concerns the gene FLT3 and acute myeloid leukemia.